Abstract
Thromboembolic disorders are the major cause of mortality and morbidity in Western societies. Coagulation enzymes, such as thrombin, factor Xa and a tissue factor/factor VIIa complex, together with platelet GPIIb/IIIa receptors, are the focal point of attention in pharmaceutical research aimed at finding new antithrombotic agents. However, finding orally active drugs for these particular molecular targets has proved to be anything but straightforward. Thrombin, factor Xa, tissue factor/factor VIIa and platelet GPIIb/IIIa receptors display a preference for molecules containing highly basic arginine and/or acidic aspartate moieties, which are, however, associated with poor bioavailability after oral application. Different approaches have been taken to achieve favourable absorption, metabolism, distribution and clearance, without compromising the antithrombotic activity of the compounds. This review highlights the use of the prodrug principle in optimising antithrombotic agents.
Keywords: Antithrombotic, prodrug, thrombin, factor Xa, factor VIIa, platelet
Current Pharmaceutical Design
Title: Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle
Volume: 12 Issue: 1
Author(s): L. Peterlin-Masic, J. Cesar and A. Zega
Affiliation:
Keywords: Antithrombotic, prodrug, thrombin, factor Xa, factor VIIa, platelet
Abstract: Thromboembolic disorders are the major cause of mortality and morbidity in Western societies. Coagulation enzymes, such as thrombin, factor Xa and a tissue factor/factor VIIa complex, together with platelet GPIIb/IIIa receptors, are the focal point of attention in pharmaceutical research aimed at finding new antithrombotic agents. However, finding orally active drugs for these particular molecular targets has proved to be anything but straightforward. Thrombin, factor Xa, tissue factor/factor VIIa and platelet GPIIb/IIIa receptors display a preference for molecules containing highly basic arginine and/or acidic aspartate moieties, which are, however, associated with poor bioavailability after oral application. Different approaches have been taken to achieve favourable absorption, metabolism, distribution and clearance, without compromising the antithrombotic activity of the compounds. This review highlights the use of the prodrug principle in optimising antithrombotic agents.
Export Options
About this article
Cite this article as:
Peterlin-Masic L., Cesar J. and Zega A., Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle, Current Pharmaceutical Design 2006; 12 (1) . https://dx.doi.org/10.2174/138161206775193172
DOI https://dx.doi.org/10.2174/138161206775193172 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Oxytocin in Neuropsychiatric Disorders
Current Medicinal Chemistry Status of Anti-Lung Cancer Drug Patents Applications in China from 2003 to 2012
Recent Patents on Anti-Cancer Drug Discovery 4’-Aminochalcones As Novel Inhibitors of the Chlorinating Activity of Myeloperoxidase
Current Medicinal Chemistry Angiogenesis and Blood-Brain Barrier Permeability in Vascular Remodeling after Stroke
Current Neuropharmacology G-protein Dependent Platelet Signaling - Perspectives for Therapy
Current Drug Targets Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Current Medicinal Chemistry Therapeutic Potential of 5-HT7 Receptors in Mood Disorders
Current Drug Targets Poly(ε-caprolactone) Films with Favourable Properties for Neural Cell Growth
Current Topics in Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Current Gastrointestinal Imaging in Children
Current Pediatric Reviews Synthesis of Benzo[d]imidazo[2,1-b]thiazole-Propenone Conjugates as Cytotoxic and Apoptotic Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Quorum Sensing Inhibitors as Anti-Biofilm Agents
Current Pharmaceutical Design Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy
Current Drug Targets Most Efficient Routes for the Synthesis of α,β-Diamino Acid-Derived Compounds
Current Pharmaceutical Design Targeting to 5-HT1F Receptor Subtype for Migraine Treatment: Lessons from the Past, Implications for the Future
Central Nervous System Agents in Medicinal Chemistry Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design